Table 1.
Patient Baseline and Disease Characteristics
| Characteristic | Rolapitant 180 mg (n = 192) | Control (n = 209) |
|---|---|---|
| Age, median (range), y | 61 (31–83) | 64 (23–88) |
| Sex, No. (%) | ||
| Female | 104 (54.2) | 116 (55.5) |
| Male | 88 (45.8) | 93 (44.5) |
| Alcohol consumption, No. (%)a | ||
| 0 to ≤5 drinks/wk | 176 (92.1) | 184 (88.0) |
| >5 drinks/wk | 15 (7.9) | 25 (12.0) |
| Primary tumor site, No. (%) | ||
| Lung | 97 (50.5) | 112 (53.6) |
| Ovary | 33 (17.2) | 22 (10.5) |
| Breast | 21 (10.9) | 34 (16.3) |
| Uterus | 13 (6.8) | 18 (8.6) |
| Head and neck | 3 (1.6) | 4 (1.9) |
| Other | 25 (13.0) | 19 (9.1) |
| Receipt of concomitant emetogenic chemotherapy, No. (%)b | ||
| Yes | 26 (13.5) | 37 (17.7) |
| No | 166 (86.5) | 172 (82.3) |
a
Based on self‐reported data (191 patients in the rolapitant group).
b
Hesketh level ≥ 3.